BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/15/2020 8:19:14 AM | Browse: 840 | Download: 1371
 |
Received |
|
2020-02-20 08:58 |
|
Peer-Review Started |
|
2020-02-20 09:00 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-04-18 21:27 |
|
Revised |
|
2020-05-08 18:23 |
|
Second Decision |
|
2020-05-25 07:20 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-05-27 19:00 |
|
Articles in Press |
|
2020-05-27 19:00 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-05-31 23:47 |
|
Typeset the Manuscript |
|
2020-06-12 01:55 |
|
Publish the Manuscript Online |
|
2020-06-15 08:19 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Observational Study |
| Article Title |
Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Bao-Jiang Liu, Song Gao, Xu Zhu, Jian-Hai Guo, Xin Zhang, Hui Chen, Xiao-Dong Wang and Ren-Jie Yang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Foundation of Chinese Geriatric Oncology Society |
CGOS-01-2012-1-00800 |
|
| Corresponding Author |
Xu Zhu, MD, PhD, Chief Doctor, Full Professor, Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), No. 52, Fucheng Road, Haidian District, Beijing 100142, China. drzhuxu@163.com |
| Key Words |
Hepatocellular carcinoma; Transcatheter arterial chemoembolization; Hepatic arterial infusion chemotherapy; Oxaliplatin; Fluorouracil; Sorafenib |
| Core Tip |
oth hepatic arterial infusion chemotherapy (HAIC) and sorafenib plus transcatheter arterial chemoembolization (TACE) combination therapy are widely used as a treatment of choice in patients with hepatocellular carcinoma (HCC) in Asia. However, the safety and efficacy of sorafenib combined with HAIC (folinic acid, 5-fluorouracil and oxaliplatin) after TACE for intermediate and advanced HCC have not been firmly established. In the present study, we confirmed the treatment efficacy and safety of this combination therapy. We believe that this study can help doctors and patients to select appropriate therapy. |
| Publish Date |
2020-06-15 08:19 |
| Citation |
Liu BJ, Gao S, Zhu X, Guo JH, Zhang X, Chen H, Wang XD, Yang RJ. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(6): 663-676 |
| URL |
https://www.wjgnet.com/1948-5204/full/v12/i6/663.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v12.i6.663 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
